Clinical Trials Logo

Clinical Trial Summary

The optimal dose of iodine based contrast agents used in contrast-enhanced spectral mammography (CESM) is unknown. If CESM, performed with lower dose of iodine based contrast agent, visualizes a tumor comparable to CESM with regular dose of contrast agent, patients can receive less contrast agent for CESM in future and thereby risking less side effects of the contrast agent. In order to study whether CESM remains unchanged at smaller amounts of contrast administration, a second CESM exam will be performed within one week of the first with a an alternative amount of contrast, it being either 80%, 60% or 40% of the original contrast dose. The settings of the CESM unit will remain unchanged.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT03008031
Study type Interventional
Source Maastricht University Medical Center
Contact
Status Terminated
Phase N/A
Start date January 2017
Completion date April 2020

See also
  Status Clinical Trial Phase
Completed NCT03273426 - Prediction of pCR by Preoperative Biopsy in Breast Cancer With cCR After Neoadjuvant Chemotherapy. N/A
Recruiting NCT04583124 - Adjusting the Dose of Therapeutic Exercise to Prevent Neurotoxicity Due to Anticancer Treatment (ATENTO) N/A
Recruiting NCT04489173 - TAS102 in Patients With ER-positive, HER2-negative Advanced Breast Cancer Phase 2
Recruiting NCT02913573 - Effect of Pectoral Nerve Block on Post-op Pain in Patients Undergoing Mastectomy and Immediate Reconstruction Phase 2
Completed NCT03124095 - Combined Training Intervention for Women Who Underwent Primary Treatment for Breast Cancer N/A
Terminated NCT00251095 - Comparison of Safety and Efficacy of TOCOSOL(R) Paclitaxel Versus Taxol(R) for Treatment of Metastatic Breast Cancer Phase 3
Completed NCT05576545 - Develop and Evaluate the Effectiveness of a Self-Care Smartphone Application on the Self-Efficacy, and Resilience Among Newly Diagnosed Breast Cancer Patients Undergoing Treatment N/A
Active, not recruiting NCT03625635 - Effect of a Clinical Nutrition Intervention Program in Breast Cancer Patients During Antineoplastic Treatment N/A
Recruiting NCT04799535 - Quantitative Microvasculature Imaging for Breast Cancer Detection and Monitoring
Withdrawn NCT03266562 - Estrogen Receptor Expression in Breast Cancer - Assessed With Positron Emission Mammography N/A
Completed NCT00530868 - Comparing Letrozole Given Alone to Letrozole Given With Avastin in Post-Menopausal Women Breast Cancer Phase 2
Completed NCT06255808 - Development of Assist Tool for Breast Examination Using the Principle of Ultrasonic Sensor
Completed NCT04640220 - Improvement of Range of Motion in Frozen Shoulder in Breast Cancer Survivors N/A
Completed NCT02970682 - SFX-01 in the Treatment and Evaluation of Metastatic Breast Cancer Phase 2
Completed NCT02316561 - Single Dose Ablative Radiation Treatment for Early-Stage Breast Cancer N/A
Terminated NCT00638963 - Temozolomide as a Prophylaxis Against Brain Recurrence in Participants With Metastatic Breast Cancer (P05225 AM2) Phase 2
Terminated NCT00249301 - A Study of MLN8054 in Patients With Advanced Solid Tumors Phase 1
Not yet recruiting NCT06056414 - Study of Anxiety After a Session of Energy Resonance by Cutaneous Stimulation N/A
Recruiting NCT05427071 - Magnetic Marker Localization for Occult Breast Cancer and Target Axillary Dissection in Node-positive Breast Cancer Post-neoadjuvant Chemotherapy N/A
Recruiting NCT03740893 - PHOENIX DDR/Anti-PD-L1 Trial: A Pre-surgical Window of Opportunity and Post-surgical Adjuvant Biomarker Study of DNA Damage Response Inhibition and/or Anti-PD-L1 Immunotherapy in Patients With Neoadjuvant Chemotherapy Resistant Residual Triple Negative Breast Cancer Phase 2